The 'Anyone But China Safe Drug Act' mandates federal health programs to purchase drugs with active pharmaceutical ingredients (APIs) manufactured outside of China, phasing in requirements from 2028 to 2030. This legislation provides significant tax incentives for domestic pharmaceutical and medical device manufacturing, directly benefiting U.S.-based drug and device producers. Companies with robust U.S. manufacturing capabilities will gain market share and financial advantages.
TICKER INTELLIGENCE
$ALC
Company & Legislative Profile
$ALC is a publicly traded company in the Healthcare sector. This company operates across Healthcare and is subject to various Congressional legislative and regulatory actions. HillSignal is tracking 1 active Congressional signal mentioning $ALC, including 1 bill. The current legislative sentiment is predominantly bullish, suggesting potential tailwinds from government policy.
$ALC is currently facing 1 active congressional signal tracked by HillSignal. With 1 bullish, and 0 bearish signal, the average legislative impact score is 7.0/10. Key sectors affected include Healthcare and Manufacturing. Recent major catalysts include Technology Administration Authorization Act For Fiscal Years 2001, 2002, and 2003. Below is the complete tracker of government activity affecting $ALC’s market performance.
1
Total Signals
7.0/10
Avg Impact
1
Bullish Signals
0
Bearish Signals
Related Sectors
Recent Congressional Signals for $ALC
Understanding These Signals
Get Full Access to $ALC Signals
Daily AI-analyzed alerts for Congressional activity affecting your portfolio.
Become a Member →